Wednesday, August 19, 2015 8:10:19 PM
OCAT the next REGN
OCAT just raised cash today in a very creative non-dilutative financing. They are about to start an efficacy trial for dry age-related macular degeneration (AMD) and a pivotal trial for Stargardt's macular degeneration (SMD). The stock was up 12% today. OCAT only has 40 million shares outstanding, and a market cap of only $150 million. Once they confirm the efficacy they saw in the P1 trial, this stock is going to $300 plus. The market, as REGN investors know, for AMD is HUGE!
Time to take some profits off the table here and invest them in OCAT, in my humble opinion. I see OCAT as being the next REGN and then some.
Recent REGN News
- Regeneron Provides Update on Biologics License Application for Odronextamab • GlobeNewswire Inc. • 03/25/2024 11:00:02 AM
- High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization • PR Newswire (US) • 03/13/2024 03:55:00 AM
- High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization • GlobeNewswire Inc. • 03/13/2024 01:30:22 AM
- Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol • GlobeNewswire Inc. • 03/11/2024 11:00:23 AM
- EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet • GlobeNewswire Inc. • 03/08/2024 12:00:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:01:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:01:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 09:14:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:04:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:04:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:04:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:34:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:07:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:07:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:07:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:07:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 08:25:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2024 09:04:37 PM
- Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation • GlobeNewswire Inc. • 02/23/2024 06:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/22/2024 10:10:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/22/2024 09:06:01 PM
- Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review • GlobeNewswire Inc. • 02/21/2024 12:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:03:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 09:15:32 PM
- Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU) • GlobeNewswire Inc. • 02/16/2024 05:59:00 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM